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EpitopeThe global challenge for solid organ transplantation programs is to distribute organs to the highly sensitized
recipients. The purpose of this work is to describe and test the functionality of the EpHLA software, a program
that automates the analysis of acceptable and unacceptable HLA epitopes on the basis of the HLAMatchmaker
algorithm. HLAMatchmaker considers small conﬁgurations of polymorphic residues referred to as eplets as es-
sential components of HLA-epitopes. Currently, the analyses require the creation of temporary ﬁles and the
manual cut and paste of laboratory tests results between electronic spreadsheets, which is time-consuming
and prone to administrative errors.
Results: The EpHLA software was developed in Object Pascal programming language and uses the HLAMatch-
maker algorithm to generate histocompatibility reports. The automated generation of reports requires the in-
tegration of ﬁles containing the results of laboratory tests (HLA typing, anti-HLA antibody signature) and
public data banks (NMDP, IMGT). The integration and the access to this data were accomplished by means
of the framework called eDAFramework. The eDAFramework was developed in Object Pascal and PHP and it
provides data access functionalities for software developed in these languages. The tool functionality was
successfully tested in comparison to actual, manually derived reports of patients from a renal transplantation
program with related donors.
Conclusions: We successfully developed software, which enables the automated deﬁnition of the epitope
speciﬁcities of HLA antibodies. This new tool will beneﬁt the management of recipient/donor pairs selection
for highly sensitized patients.ble Mismatches; GUI, Graphical
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The interaction among HLA molecules and antibodies has been in
the limelight among researchers and clinicians in the history of organ
transplantation. Patel and Terasaki showed with lymphocytotoxicitycross-match tests [1] a correlation between donor-reactive antibodies
and poor graft survival, and this made this test a mandatory pre-
transplant evaluation [2]. Subsequently, issues were raised about
the sensitivity and speciﬁcity of the complement dependent lympho-
cytotoxicity assays (CDC), and this led to the development of the solid
phase assay methods (SPA) which are now used on a worldwide
basis. Especially single allele panels have been useful to test for HLA
antibodies [3]. This technique has also been used to predict cross-
matches in sensitized candidates and to monitor the development
of clinically relevant HLA antibodies post-transplant.
A new outlook of the HLA–antibody interaction in the transplanta-
tion context was reported when Rene Duquesnoy reasoned that the
antibody interacts not with “HLA antigens”, but with structurally de-
ﬁned epitopes called eplets, present in the HLA molecules. According
to this hypothesis, different HLA molecules will be recognized by the
same antibody if such HLAmolecules have one or more eplets in com-
mon recognized by that antibody [4]. Characterizing eplet-speciﬁc
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sense, AMM are HLA antigens which differ from the patient's own
HLA antigens, but they do not have antibody-eplets. Realizing that
establishing AMM increases the transplantation chances in highly
sensitized patients,Duquesnoy and collaborators developed HLA-
Matchmaker, a donor–recipient compatibility algorithm based on
eplets that may react with antibodies [5]. This algorithm, validated
by the Eurotransplant group, increases the rate of transplantation
among highly sensitized recipients with a shorter waiting time. In
fact, every highly sensitized recipient entering the AMM Program
has a 43% chance of receiving a transplant within 12 months, or 58%
within 21 months. The follow-up of these recipients showed that
the graft survival at two years is 87%, the same result as that observed
for non-sensitized recipients transplanted in the same period [6].
These results, which were conﬁrmed by other groups [7–9], point to
AMM Program as an alternative for transplantation of highly sensiti-
zed recipients against HLA antigens.
Data Input for HLAMatchmaker algorithm is a set of data resulting
from the screening for the presence of HLA antibodies in the recipient's
serum (SPA Results). Data output from HLAMatchmaker is a set of
eplets that permits an expert laboratory personnel working in the HLA
ﬁeld to identify AMM. Unfortunately, both input data into HLAMatch-
maker and output data analyses are manually performed with labor-
intensive Microsoft Excel programs, which limit applying the eplet -
concept in the clinically oriented HLA laboratory. Currently, there is
no software automating the input and output data analysis for HLA-
Matchmaker. A computerized tool and a centralized relational database
would reduce potential analyses errors, increasing reproducibility of
histocompatibility studies, facilitating the data management and mak-
ing data analysis less labor-intensive and more clinically applicable.
The EpHLA software has been developed to carry out HLAMatchma-
ker in HLA laboratories that serve clinical transplant programs. It pro-
vides searches with a non-redundant and structured local database
managed through a graphical user interface (GUI).
2. Objectives
The purpose of this work is to describe and test the functionality of
the EpHLA software, a program that automates the analysis of acceptable
and unacceptable HLA epitopes on the basis of the HLAMatchmaker
algorithm.
3. Materials and methods
3.1. Execution
EpHLA is built in theObject Pascal programming language anduses an
MS-Access (http://ofﬁce.microsoft.com/pt-br/access/default.aspx) [10]
or MySQL (http://www.mysql.com/) [11] database to store clinical and
genetic data. In order to ease data integration between HLAMatchmaker,
Solid Phase Assay (SPA) results and web repositories, we developed the
easy Data Access framework (eDAframework). This framework was de-
veloped in Object Pascal (http://delphi.com/) [12] and PHP (Hypertext
Preprocessor — http://www.php.net/) [13] programming languages and
provides import, data access and export functionalities. The import func-
tionality allows the importing of data from different ﬁle formats (FASTA,
text ﬁles, comma separated values and Excel spreadsheet— http://ofﬁce.
microsoft.com/pt-br/excel/default.aspx [14]) to laboratory local data-
bases, releasing them to access at only one repository. Such data can be
accessed through eDAframework and used for processing through the
EpHLA software. The results of this processing are exported as Excel
spreadsheets using the export functionality.
The EpHLA software uses the HLAMatchmaker algorithm to ﬁnd
acceptable and unacceptable mismatches for HLA sensitized recipi-
ents. The input data to the HLAMatchmaker algorithm are: donor
and recipient's HLA alleles, serum date, cutoff value and the SPAresults. However, if high resolution HLA alleles are not available, allele
frequencies databases can be queried in order to deﬁne the most like-
ly allele for each case. The HLAMatchmaker algorithm works by com-
paring eplets found in donor and recipient's HLA molecules,
generating a list of matches and mismatches for each other. The re-
ports generated by EpHLA program allow laboratory personnel to di-
vide potential donors into three different categories: (i) full HLA
match; (ii) acceptable mismatches, and (iii) unacceptable mis-
matches. Note that if donor and recipient HLAmolecules are identical,
their eplets are identical too, and the transplant is acceptable. On the
other hand, if organ donor/recipient HLA molecules are not identical,
two cases are possible: (i) The recipient has preformed antibodies
against donor eplets; (ii) The recipient does not have antibodies
against donor eplets. In the ﬁrst case, there is a higher risk associated
with the transplantation, and in the second one, there is a lower risk
[2, 15].
3.2. Using the system
The EpHLA program runs without complex setup procedures: the
user has only to copy its ﬁles to drive C on a computer executing the
Windows or MAC operational system (using a virtual machine). The
EpHLA software consists of an executable program (EpHLA.exe), a re-
lational database and auxiliary directories, as shown in the directory
tree of Fig. 1, [A].
The EpHLA program's workﬂow consists of ﬁve steps: 1. Prepara-
tion of CSV ﬁles with the SPA results; 2. The processing of one or
more CSV ﬁles; 3. The inclusion of the HLA alleles from recipient
and donor; 4. Deﬁnition of cutoff value of SPA results; and 5. Genera-
tion of the Histocompatibility Map report.
Preparation of CSV ﬁles is related to transferring CSV ﬁles to the
input directory of the EpHLA program's directory tree. The CSVﬁles cop-
ied to the input directory are shown in the form Available CSV ﬁles in di-
rectory (Fig. 1, [B]). Using this form, one or more ﬁles can be selected
and processed (workﬂow's second step). The EpHLA software uses in-
formation available in the HLAMatchmaker program's spreadsheets
([5] http://www.hlamatchmaker.net), including class of HLA and lot
number of SPA kits (obtained from the manufacturer — Fig. 1, [C]).
The result of the processing is available in the EpHLA— Local repository
form. This form contains information on the recipient and his/her SPA
results. Thus, one must access the Local repository form of the EpHLA
software and type in the class I and class II HLA alleles of the recipient
and donor.
The next step is to determine the cutoff value. The standard value
of the EpHLA program is 500 of Median-Fluorescence Intensity (MFI).
However, the laboratory personnel can deﬁne the value or alter to the
suggested value in section Calculated Cutoff, according to Rene
Duquesnoy [16] (Fig. 2). In the last step, the EpHLA program executes
the HLAMatchmaker algorithm to generate the Histocompatibility
Map report. During this step, the recipient's eplets of the self HLA
molecules are removed from the histocompatibility analysis; the
remaining eplets (non-self) are shown in the Histocompatibility
Map report and classiﬁed by the EpHLA program as potentially or
weakly immunogenic based on the adopted MFI cutoff value. All al-
leles of the panel whose MFI is lower than the cutoff established by
the laboratory personnel will have its eplets classiﬁed as weakly im-
munogenic in all HLA molecules studied. These eplets are shown in
blue. Otherwise, the eplet is considered potentially immunogenic
and is typed black or red. A black eplet means that it is not the only
eplet responsible for immunogenicity of the HLA molecule. On the
other hand, a red eplet stands for a unique eplet responsible for im-
munogenicity in at least one HLA molecule for the tested serum
whose MFI value is larger than the cutoff.
The Histocompatibility Map report from the EpHLA program con-
tains two tabsheets: (i) Eplets Map and (ii) Eplet's Report. Eplets Map
contains ﬁve predictable tabs groupings: Acceptable Mismatches, No
Fig. 1. EpHLA's screenshots.
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Mismatches (Fig. 3). These tabs allow the laboratory personnel to vi-
sualize, to order and to group HLA alleles so as to improve the histo-
compatibility study of the recipient/donor pair.Fig. 2. Local repository form with recipient's HLA allThe Recipient × Donor tab shows the donor's HLA antigens and his/
her eplets easing the immunological risk deﬁnition associated to the re-
cipient/donor pair in the study. In this tab, the laboratory personnel by
analyzing the class II HLA eplets will be able to visualize the eplets ofeles, Solid Phase Assay results and cutoff value.
Fig. 3. EpHLA software's Histocompatibility Map report.
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that this tab was idealized to allow only the visualization of eplets. For
that reason, in the Recipient × Donor tab the EpHLA Software shows
zero for theMFI value of the subunits DQA1* andDQB1* shown separate-
ly in the columns “Normal” (Figs. 5 and 6). The actual MFI values associ-
ated to the beads of the panel containing the subunits DQA1* and DQB1*
studied can be visualized in the remaining tabs.
The Histocompatibility Map report also shows in the upper right
corner the Eplet's Report tab, where the laboratory personnel can easily
verify if an eplet plays a potential role in allosensitization and observe,
quickly, if a certain eplet appears only in positive molecules or also in
negative ones (Fig. 3).
In order to carry out the post-transplant follow-up or to study thepo-
tential donors for a certain recipient, the EpHLA program allows regis-
tering for donor on the Local repository form. It is only necessary to
register the following data: name, laboratory unique number and the
HLA alleles, represented by the ﬁelds A, B, Cw, DRB1, DRB3, DRB4,
DRB5, DQA and DQB. One or more registers of potential donors can be
associated to a recipient registration — using the Potential Donors tab
accessible on the Local repository form. For each recipient/donor pair,
the EpHLA program generates a report showing the donor's alleles and
their respective non-self eplets, as previously shown.
3.3. Case reports
To test the tool's functionalities, the EpHLA software was used to
determine the antibody proﬁle of two sensitized recipients from the
renal transplant program studied at the Federal University of Piauí's
Immunogenetics and Molecular Biology Laboratory (LIB-UFPI). The
ﬁrst recipient exhibited a positive CDC assay with B-lymphocytes
due to IgG antibodies, and the second recipient had a negative CDC
assay with a current serum and a positive CDC assay with historical
serum.Table 1
Recipient 1 and donor HLA type.
Locus A⁎ B⁎ DRB1⁎
Recipient 02:01, 24:03 35:04, 49:01 08:04, 11:01
Donor (mother) 02:01, 24:03 15:04, 35:04 08:04, 16:01
⁎ There are preformed antibodies against DRB5*02:02, this mismatch is shown in bold.The HLA typings were carried out at medium-resolution using
Sequence-speciﬁc Oligonucleotide Probe Hybridization – SSOPH
(One Lambda, Canoga Park, CA, USA) – for the loci A, B, Cw, DRB1,
DQB1. HLA alleles were inferred using the NMDP codes and the allele
frequency tables available at http://bioinformatics.nmdp.org/ [17].
The HLA alleles of the loci DRB345 and DQA1 were generated on
the basis of their linkage with the DRB1 allele, using the HLAMatch-
maker software (DRDQ Allele Antibody Screen) — available at
http://www.hlamatchmaker.net/ [5].
In this study we used the following MFI cutoff values to classify
antibody–antigen reactions: strong reaction — MFI higher than
3,000; moderate reaction — MFI between 500 and 3,000, and weak
or negative reaction — lower than 500.
In order to obtain the calculated PRA we used the public
program cPRA, available at Organ Procurement and Transplan-
tation Network's website: http://optn.transplant.hrsa.gov/resources/
professionalResources.asp?index=78[18], using as input data the
HLA antibody speciﬁcities, which were considered Unacceptable
Mismatches.
The study was approved by the Research Ethics Committee of UFPI
with the number 0153.0.045.000-10, and informed consent was
obtained from recipients and relatives prior to inclusion, according
to the Declaration of Helsinki.4. Results
4.1. Case 1
A 55-year-old man with CDC assay negative received a kidney transplant from his
mother (Table 1). Eight years after transplantation he lost the kidney by chronic rejec-
tion. A serum screen of this recipient using single class I and II allele SPA Luminex
panels (Labscreen; OneLambda, Canoga Park, CA) revealed the presence of anti-class
II donor speciﬁc antibodies (anti-DRB5*02:02) as well as non-donor speciﬁc antibodies
(Fig. 4).DRB3⁎ DRB5⁎ DQA1⁎ DQB1⁎
02:02 – 04:01, 05:01 03:01, 03:01
– 02:02 04:01, 01:02 03:01, 05:02
Fig. 4. Histocompatibility Map report generated by the EpHLA software from case 1.
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never exposed. In order to solve this problem we used the EpHLA software. A closer
view of results in the EpHLA's Histocompatibility Map report showed that all HLA mole-
cules to which the recipient developed antibodies share eplets with DRB5*02:02 from
the immunizer. Interestingly, the DRB5*02:02 molecule has three potentially immuno-
genic eplets: 6C, 71QAA, 108T3. We noted that while 6C eplet appears only on
DRB5*02:02 molecule, the 71QAA eplet is shared by molecules of serum group DR15
(DRB1*15:01, DRB1*15:02, DRB1*15:03) and the 108T3 eplet is shared by DRB5*01:01
(Fig. 4). Thus, we were able to identify the epitopes targeted by the recipient's HLA anti-
bodies using the EpHLA software, and the alleles DRB5*02:02, DRB5*01:01, DRB1*15:01,
DRB1*15:02, DRB1*15:03 are the unacceptable mismatches for this case; they are associ-
ated to a 28% cPRA.4.2. Case 2
A 35-year-old female in chronic hemodialysis, enrolled in the related renal trans-
plantation program with two potential donors (brothers). The donors were typed as
identical HLA each other and distinct as regards the recipient (Table 2). The result of
the T and B CDC assays were positive to both donors. Four years later, the CDC assays
performed with the same donors were negative and ﬂow cytometry crossmatches
were positive for T and B cells.
The SPA results using current serum showed preformed antibodies directed to amyr-
iad of different class I and II HLA antigens (cPRA=91%). The possible immunization
events were blood transfusions and three gestations from the same husband, whose
HLA typing is shown in Table 2. A closer examination of the SPA results revealed: (i) spe-
ciﬁc antibodies against the husband's HLA mismatches, including allele A*02:01
(MFI=8,994), and (ii) antibodies against potential donors' HLA antigens, including allele
A*68:02 (MFI=12,353). Because A*02:01 and A*68:02 alleles belong to the same CREG,
we reasoned that such alleles could share the same eplet targeted by the recipient's HLA
antibodies.Table 2
HLA type from recipient 2, donors and potential immunizer.
Locus A⁎ B⁎ Cw⁎ DRB1⁎
Patient 03:01, 24:02 07:02, 35:01 03:04, 07:02 03:01, 15:
Potential Donors 23:01, 68:02 15:18, 15:10 03:04, 03:04 07:01, 08:
Immunizer 02:01, 30:02 49:01, 57:03 07:01, 18:01 11:01, 13:
⁎ There are preformed antibodies against the mismatches shown in bold.We tested our hypothesis using the EpHLA software analyzing recipient versus immuni-
zer, and then versus potential donors (Figs. 5 and 6). We found that the recipient HLA anti-
bodies recognize the pair of eplets 142MT+145KHA. Such eplets are shared by the HLA
allele A*02:01 from the immunizer and allele A*68:02 from potential donors (Figs. 6 and
7). As showed in Table 2, the immunizer and potential donors share the same beta subunit
in the HLA DQ molecule (DQB1*03:01), however combined to different alpha subunits.
Such beta subunit presents an only potentially immunogenic eplet: 45EV. Nevertheless, as
the MFI value of the HLA heterodimer DQA1*02:01–DQB1*03:01 of the potential donors is
921, the immunological risk is low for class II HLA. Contrariwise, we were able to detect a
strong reactivity against A*68:02, representing a high immunological risk for antibody-
mediated rejection.
As there is no agreement upon current CDC assaywith theﬂowcytometry crossmatch
and SPA results, we believe that the recipient has a mixture of antibodies with a preva-
lence of non-ﬁxing complement isotypes, or the titles of theﬁxing complement antibodies
present in the current serumwere not enough to activate the classic pathway of the com-
plement system.
Thus, the potential donors' allele A*68:02 is considered one of the unacceptable
mismatches for this recipient. As the calculated PRA was 91%, this case exempliﬁes
the importance of using the Acceptable Mismatch approach.5. Discussion
The implementation of the EpHLA program will allow a simple and
automated analysis of antibodydata using theHLAMatchmaker algorithm
and prevent the many laborious manual steps used in the current ana-
lyses. Based on the HLA types of the recipient/donor pair and the SPA re-
sult, it is possible to generate reports automaticallywhichwill support the
transplantation team to deﬁne the risk of developing antibody-mediatedDRB3⁎ DRB4⁎ DRB5⁎ DQA1⁎ DQB1⁎
01 01:01 – 01:01 05:01, 01:02 02:01, 05:02
04 – 01:01 – 02:01, 04:01 02:01, 03:01
03 02:02, 01:01 – – 01:02, 05:01 06:02, 03:01
Fig. 5. Histocompatibility Map report generated by the EpHLA software from case 2 versus immunizer.
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generating results with at least the same degree of accuracy [19].
Automation will certainly decrease the incidence of administrative
errors and facilitate the information management within the organiza-
tion [20].
6. Conclusions
In conclusion, the EpHLA program integrates SPA results and the
HLAMatchmaker algorithm in an automated histocompatibility analysis.
The program will certainly beneﬁt the donor selection and risk assess-
ment for HLA sensitized recipients.
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